Metabolic & Weight ManagementIn StockMetabolic & Weight Management
Retatrutide
Also known as: LY3437943, Triple GLP-1/GIP/glucagon receptor agonist
Investigational 39-amino-acid triple receptor co-agonist peptide targeting GLP-1, GIP, and glucagon receptors.
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide engineered as a balanced co-agonist at three incretin-family receptors: GLP-1, GIP, and glucagon (GCGR).
It incorporates non-coded amino acid residues (Aib at positions 2 and 20, α-methyl-Leu at position 13) and a C20 fatty diacid for albumin binding.Developed by Eli Lilly, Retatrutide is currently in Phase 3 clinical trials and is not FDA-approved for any indication.
A Phase 2 trial published in The New England Journal of Medicine in 2023 demonstrated significant metabolic effects across the GLP-1/GIP/glucagon triple-agonism profile.In preclinical and in-vitro research, Retatrutide is studied for its unique tri-receptor activation profile, providing a comparison tool against single-agonist (semaglutide) and dual-agonist (tirzepatide) compounds.
Research applications
- Triple-receptor (GLP-1/GIP/GCGR) co-agonist pharmacology
- Comparative incretin-receptor research
- Metabolic-peptide receptor-biology
- Balanced agonism research
- Next-generation incretin-compound design
Technical profile
- Net content
- 5 mg
- Molecular formula
- See Certificate of Analysis
- Molecular weight
- ~4731 g/mol
- CAS
- 2381089-83-2
- Sequence
- 39-amino-acid sequence with Aib2, Aib20, αMeLeu13, and C20 diacid modification
For research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease. Catalog availability restricted to verified licensed practitioners.
Retatrutide is a triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. This tri-receptor approach provides synergistic effects on weight management, glucose homeostasis, and energy expenditure in preclinical research.
